SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNFA is trending due to its strategic shift into quantum computing and a name change, sparking excitement and speculation about its potential in the cryptocurrency sector. Community discussions revolve around the company's new direction, potential for a short squeeze, and upcoming news catalysts. Some traders express concerns about dilution and past performance, while others are optimistic about the company's technology and future prospects.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas is trending due to reports of potential equity stake by the Trump administration, sparking significant community discussion around government involvement and the future of lithium supply. The news has triggered a massive surge in trading volume as investors weigh the implications for the company's Thacker Pass project and the broader lithium sector. Bullish sentiment is fueled by the possibility of reduced execution risk with government backing, while some express concerns about potential dilution and market manipulation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to positive data from its Huntington's disease gene therapy trial, with analysts raising price targets. The community is weighing the potential for accelerated FDA approval and a possible buyout, while some caution about a potential offering given the stock's surge.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a surge of interest in quantum computing stocks, fueled by a recent U.S. Air Force Research Laboratory contract. The community is debating whether the stock is overvalued, with some expecting a pullback while others remain bullish, anticipating further gains and a potential short squeeze. Discussion also involves comparisons to other quantum computing stocks and speculation about future partnerships.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following an analyst upgrade from Wells Fargo, citing expected acceleration in AWS growth driven by AI investments, sparking bullish sentiment. However, some community members express concern about Amazon's lagging performance compared to other tech giants and the broader market, with debates around its near-term direction and potential support levels. The conversation also includes discussion around upcoming catalysts like the September 30th hardware event.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions about its technology and potential in the quantum computing space, with recent advancements sparking optimism. Community members are debating its valuation and future prospects, with some citing government interest and potential executive actions as catalysts, while others express skepticism about its current profitability and revenue. The stock's movement is further fueled by short squeeze speculation, adding to the volatility and heightened interest.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Shares of Larimar Therapeutics are attracting attention, with community members pointing to option activity and chart patterns as potential catalysts. Some are hopeful for a gap closure move, while others express concerns about the lack of recent news despite the stock's upward movement. Anticipation is building regarding upcoming data releases, with some drawing comparisons to other companies in the sector.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

Iris Energy ($IREN) is trending as investors react to news of the company doubling its AI GPU fleet, targeting significant annualized AI cloud revenue by early 2026. Community discussions revolve around the potential for further price appreciation and whether $IREN can secure contracts with major AI players, with some comparing it to other high-flying stocks. The stock is also drawing attention within the context of broader AI infrastructure plays and potential analyst upgrades.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) is trending due to FDA clearance of its Prism Neuro Laser System, expanding its market reach. Community discussions revolve around the potential for increased revenue and new business opportunities stemming from the clearance. Interest in CLPT is also fueled by the broader growth in brain-related therapies and biotech investments.

$BCLAT is a meme token designed to promote transparency and honesty within its community. Its goal is to create an open and transparent ecosystem that provides its users with a safe and fair platform. That is why all details of locked liquidity, developers/marketing wallets, etc., are shown.  $BCLAT is not just a meme token; it also represents values such as transparency, honesty, and community spirit. The aim is to build a community based on these values and encourage its members to actively participate in the development and decision-making of the community.

Bomboclat

Bomboclat ($BCLAT.X) is trending as community members express bullish sentiment, anticipating significant gains and upward momentum. The crypto is being recognized for its potential, with many highlighting its breakout and strong chart activity. Community members are actively encouraging others to buy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TNF Pharmaceuticals, Inc. (TNFA) announced on Wednesday that it has changed its corporate name to Q/C Technologies and will begin trading under a new ticker on the Nasdaq Capital Market starting Thursday.TNF Pharmaceuticals stated that no action is required from current shareholders regarding the name change. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tnfpharma.com/news-events/press-releases/detail/81/tnf-pharmaceuticals-announces-name-change-to-qc">noted</a> that the new name represents the company’s recent strategic pivot into quantum-class computing. The company has exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system for application in the cryptocurrency vertical.LPUs can reduce energy consumption by up to 90% while outperforming traditional GPUs and quantum computing in both speed and efficiency, the company said. Lighsolver’s architecture is further designed to improve security for blockchain operations and is expected to position the company at the forefront of innovation in blockchain infrastructure, the company said.Following the announcement, <a href="https://stocktwits.com/symbol/TNFA">TNFA shares</a> surged by about 101% by the afternoon of Wednesday. On Stocktwits, retail sentiment around TNFA jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels. The stock will begin trading under the new ticker symbol QCLS starting Thursday, September 25.The company added that it also continues to evaluate strategic options for its therapeutic programs, Isomyosamine and Supera-CBD. While Isomyosamine has potential for the treatment of chronic inflammation, Supera-CBD holds potential in managing addiction. The company is looking to realize maximum value from these assets as it undertakes the pivot into computing and blockchain infrastructure.TNFA stock is down by 94% this year.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TNF Pharmaceuticals Stock More Than Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.

TNF Pharmaceuticals Stock Nearly Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

Equity

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.


Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning technologies to recruit patients for its isomyosamine drug development.Isomyosamine is a drug platform based on a clinical stage small molecule that is being developed to treat diseases and disorders marked by acute or chronic inflammation.The clinical-stage pharmaceutical company stated that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.The company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.Renova CEO David Jacobs said that its technology transcends traditional big data analytics by creating highly specific patient personas.“Our platform uncovers the nuanced impact of individual physician practices—such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes—which can significantly influence cohort selection and study outcomes,” he said.Isomyosamine is the first of two therapeutic platforms being developed by TNF Pharmaceuticals. While Isomyosamine is being developed to regulate inflammation, the company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.On Stocktwits, retail sentiment around TNF remained unmoved in the ‘bearish’ territory over the past 24 hours while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1292/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_22_at_2_09_23_PM_png_87841bd4ef.webp" alt="TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits" width="1292" height="304"><figcaption>TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/TNFA">TNFA stock</a> is down by over 84% so far this year and by over 93% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-says-significant-progress-made-with-india-on-trade-deal/chQSwMaRbXn">Vice President JD Vance Calls Indian PM Narendra Modi A ‘Tough Negotiator’ As US, India Negotiate Bilateral Trade Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment.

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNF or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today...

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions...

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and...

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

TNFA
TNF Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TNFA News

TNFA TNF Pharmaceuticals Inc.